The earnings underscore SI‑BONE’s transition to profitable growth, strengthening its market leadership and signaling robust upside for investors as reimbursement and product expansion accelerate.
SI‑BONE’s fourth‑quarter results illustrate how a focused innovation strategy can translate into tangible financial upside. Revenue growth was driven by both domestic strength—13.9% U.S. sales increase—and a surge in international demand for iFuse TORQ, which grew nearly 39% quarter‑over‑quarter. The company’s ability to lift gross margins above 79% reflects a favorable product mix and disciplined cost controls, while operating expense growth remained modest relative to top‑line expansion, reinforcing operating leverage.
Beyond the headline numbers, the firm’s reimbursement wins are reshaping its addressable market. New Technology Add‑On Payments and Transitional Pass‑Through status for iFuse TORQ TNT and Bedrock Granite have boosted facility reimbursements, especially as CMS expands outpatient and ASC payment structures. The inclusion of the open SI‑joint fusion code in TPT calculations and a 17% Medicare uplift for office‑based labs further improve the economics for physicians, accelerating adoption across care settings.
Looking ahead, the Smith+Nephew trauma partnership and the pipeline of breakthrough devices—Intra TI clearance and a third device slated for late‑2026 launch—position SI‑BONE to capture new clinical adjacencies. With 2026 revenue guidance of $228‑$232 million and a projected 78% gross margin, the company is poised to sustain its profitability trajectory while expanding into high‑growth ASC and trauma segments, offering investors a compelling growth narrative anchored in innovation and reimbursement tailwinds.
Comments
Want to join the conversation?
Loading comments...